Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | +6.45% | 0.00% | -54.79% |
Sales 2024 * | 45.21M 62.04M | Sales 2025 * | 11.79M 16.18M | Capitalization | 140M 192M |
---|---|---|---|---|---|
Net income 2024 * | -116M -159M | Net income 2025 * | -171M -235M | EV / Sales 2024 * | -1.98 x |
Net cash position 2024 * | 229M 315M | Net cash position 2025 * | 325M 446M | EV / Sales 2025 * | -15.7 x |
P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-1.05
x | Employees | 179 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.95% |
Latest transcript on Repare Therapeutics Inc.
1 day | +6.45% | ||
Current month | +6.45% | ||
1 month | -29.79% | ||
3 months | -53.32% | ||
6 months | -5.44% | ||
Current year | -54.79% |
Managers | Title | Age | Since |
---|---|---|---|
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Steve Forte
DFI | Director of Finance/CFO | 45 | 19-09-30 |
Michael Zinda
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 19-02-28 |
Lloyd Segal
CEO | Chief Executive Officer | 60 | 16-05-31 |
Ann Rhoads
BRD | Director/Board Member | 58 | 20-06-09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.33% | 1 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 3.3 | +6.45% | 203,900 |
24-04-30 | 3.1 | -3.13% | 166,417 |
24-04-29 | 3.2 | 0.00% | 102,322 |
24-04-26 | 3.2 | +1.59% | 71,408 |
24-04-25 | 3.15 | -4.55% | 82,157 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.79% | 140M | |
+0.67% | 42.4B | |
+44.30% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- RPTX Stock